PF-29972 |
VITAMINA C Industrias Bioquímicas 500 mg Tabletas masticables sabor limón |
2018-03-10 |
|
Industrias Bioquimicas, S.A. |
Guatemala
|
Industrias Bioquímicas |
Pharmaeuropea |
Farmacias de La Comunidad Central |
Farma-Lab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30127 |
CLOSTEBOL + NEOMICINA INFASA crema topica |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30128 |
KETOCONAZOL INFASA 2% crema topica |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30129 |
KETOCONAZOL INFASA 200 mg tabletas |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30130 |
CLARITROMICINA INFASA 500 mg tabletas recubiertas |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30131 |
CLARITROMICINA INFASA 125 mg/5 mL granulado para suspensiopn oral |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30132 |
CLARITROMICINA INFASA 250 mg/5 mL granulado para suspensiopn oral |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30133 |
LORATADINA INFASA 10 mg tabletas |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30134 |
LORATADINA INFASA 5 mg5 mL jarabe |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30135 |
LANSOPRAZOL INFASA 30 mg capsulas con granulos de liberacion prolongad |
2008-03-27 |
|
Industria Farmaceutica, S.A. Infasa |
Guatemala
|
Industria Farmaceutica, S.A. Infasa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|